Introduction
Human herpesvirus 8 (HHV-8; also known as Kaposi sarcoma-associated herpesvirus, KSHV) was identified in Kaposi sarcoma lesions by representational difference analysis in 1994 [1] and belongs to the gamma group of HHVs along with Epstein-Barr virus (EBV). Kaposi sarcoma is the most common AIDS-defining malignancy in the world; in some parts of east Africa, Kaposi sarcoma is the most common cancer in the general population [2] . Multicentric Castleman disease (MCD) and primary effusion lymphoma (PEL) are uncommon neoplasms typically associated with HIV infection. Emerging insights into the pathogenesis of these disorders suggest that targeting viral functions -including lytic replication and the elaboration of lytic gene products -may be a viable strategy for preventing disease and improving response to therapy. A number of excellent reviews of HHV-8 pathobiology have been published recently [3 ,4,5] . Here, we will focus on the clinical importance of HHV-8 lytic replication and discuss the potential uses of antiviral therapies for the prevention and treatment of HHV-8-related diseases.
Role of human herpesvirus 8 lytic replication in human herpesvirus 8-associated diseases
Like all herpesviruses, HHV-8 infection of cells results in one of two discrete viral programs, latency and lytic replication. During latent infection, few viral genes are expressed and the HHV-8 genome is maintained as an episome. The HHV-8 gene products that are expressed in latently infected Kaposi sarcoma tumor ('spindle') cells appear limited to LANA-1, viral (v) cyclin, vFLIP, kaposins A, B and C, numerous miRNAs, and possibly ORF K1 (reviewed in [3 ,4] ). Each of these latent-phase proteins has functions that likely promote tumorigenesis, including promoting cell growth and division, inhibiting apoptosis, modulating inflammation, and inducing angiogenesis. Importantly, however, latent infection of primary cells with HHV-8 does not result in immortalization [6] [7] [8] [9] .
Although spindle cells in Kaposi sarcoma lesions are predominately (99%) latently infected with HHV-8, careful studies have consistently shown that a proportion undergo lytic replication and produce virions [10] [11] [12] . Most infected cell types in culture display a progressive loss of the HHV-8 episomal genome within five to 10 divisions in the absence of genetic selection or reinfection [13] , such that the HHV-8 genome is eventually lost from most spindle cell lines isolated from Kaposi sarcoma lesions [14] [15] [16] . This indicates that persistence of HHV-8 within Kaposi sarcoma tumors requires ongoing lytic replication and infection of new cells [13] . The majority of infected cells in PEL and MCD are also latent, but a greater proportion express lytic phase genes compared to Kaposi sarcoma, with MCD demonstrating the highest frequency of lytic replication (up to 25%) [11, 12, 17] .
Numerous lytic viral gene products are detected in Kaposi sarcoma tumors and mediate central aspects of Kaposi sarcoma pathobiology. Proteins expressed by spindle cells during lytic replication directly or indirectly mediate several aspects of Kaposi sarcoma pathogenesis, including inflammation (vGPCR, vIL-6, K15), angiogenesis (vIL-6, vGPCR, K1, vCCL1, vCCL2), cell growth (vIL-6, vGPCR, K1), and inhibition of apoptosis (vCCL1, vCCL2, vBcl2, vIRF1, K1), among others (reviewed in [3 ,5] ). Of note, lytically infected cells are destroyed, and thus their effects in Kaposi sarcoma lesions should be limited to either increasing the number of infected cells or paracrine effects of lytic viral gene products. Similarly, MCD appears to be driven largely by the paracrine effects of HHV-8 lytic phase proteins (e.g. vIL-6) [18] .
HHV-8 DNA is detected more frequently and at higher copy numbers in plasma of Kaposi sarcoma patients compared with controls with asymptomatic HHV-8 infection [19] [20] [21] [22] . A large proportion of this HHV-8 DNA in plasma is encapsidated in virions [21, 23] , indicating an association between Kaposi sarcoma and systemic viral replication and dissemination. HHV-8 viremia appears to be in the causal pathway for Kaposi sarcoma, rather than a consequence, as HHV-8 viremia predicts subsequent Kaposi sarcoma in cohorts of asymptomatic people with HHV-8 and HIV co-infection [24, 25] . In addition, ganciclovir, which inhibits HHV-8 lytic replication, prevents incident Kaposi sarcoma (see below). Thus, lytic replication in viral reservoirs, likely the oropharynx [22] and lymph nodes [26] , may seed the blood and increase infection of spindle cell precursors. Based on this body of evidence, therefore, HHV-8 replication appears central to the pathogenesis of Kaposi sarcoma. Evidence suggesting a causal role for HHV-8 lytic replication in the pathogenesis of Kaposi sarcoma is as follows:
(1) A proportion of HHV-8-infected spindle cells in Kaposi sarcoma lesions is consistently found to undergo lytic replication [10] [11] [12] . (2) Lytic replication is required for the maintenance of the HHV-8 genome in spindle cells [13] . (3) Gene products expressed during lytic replication mediate angiogenesis and inflammation central to Kaposi sarcoma pathogenesis (reviewed in [3 ] ). (4) HHV-8 viremia is a strong predictor for the development of Kaposi sarcoma and has been associated with a poor response during Kaposi sarcoma treatment [19, 20, [23] [24] [25] [26] [27] [28] . (5) Ganciclovir or foscarnet for treatment of cytomegalovirus (CMV) reduces the incidence of Kaposi sarcoma [29] [30] [31] [32] [33] .
Utility of measuring human herpesvirus 8 replication in the management of human herpesvirus 8-associated disease HHV-8 testing could have three potential clinical applications: diagnosing HHV-8-related disease, assessing the risk of developing disease, and predicting treatment success (Table 1) . Each possibility is reviewed in turn.
Viral testing to diagnose human herpesvirus 8-related neoplasms
In spite of its value for epidemiologic studies, serologic diagnosis of HHV-8 infection is rarely informative in clinical practice, given the relative lack of sensitivity of most assays (reviewed in [34, 35] ) combined with the fact that the majority of HHV-8-infected individuals remain asymptomatic. HHV-8 testing of biopsy specimens of [24, 25] . Therefore, it is likely that HHV-8 viral load measurement could be used to guide selective prophylaxis or preemption strategies to prevent progression from asymptomatic infection to disease, as is used for EBV and CMV in transplant patients [37, 38] . In order to develop such applications, however, the predictive value of levels of HHV-8 replication in specific patient populations must be better defined.
Human herpesvirus 8 testing to predict response to therapy or recurrent disease
The quantity of HHV-8 DNA in clinical samples has been correlated with disease progression and response to treatment in Kaposi sarcoma [28, 39, 40, 41 ] and may prove useful in guiding type or duration of therapy. Symptomatic flares of MCD are universally associated with the detection of HHV-8 DNA from the peripheral blood [42] [43] [44] , and declines in HHV-8 DNA levels in blood are associated with treatment response. Additional longitudinal studies are needed to determine how best to base management decisions on measures of HHV-8 replication in these diseases.
Use of human herpesvirus 8 DNA synthesis inhibitors
A large number of drugs that block herpesvirus DNA synthesis have been reported to inhibit HHV-8 replication (Table 2) [45-51,52 ,53 ,54] . Of these agents, ganciclovir (or its oral pro-drug valganciclovir) is the only one proven to either suppress HHV-8 replication in vivo or prevent the development of Kaposi sarcoma in randomized trials. In a randomized placebo-controlled cross-over trial, valganciclovir was shown to reduce HHV-8 oral shedding frequency by 46% and quantity by 0.44 log copies/ml [50] . Ganciclovir treatment of CMV retinitis in HIV-infected patients statistically significantly reduced the incidence of Kaposi sarcoma by 75% when given orally and 93% when given intravenously compared to intraocular treatment alone, in a randomized trial [33] . Numerous observational studies have also suggested that ganciclovir and foscarnet, but not acyclovir, may prevent Kaposi sarcoma [29] [30] [31] [32] . Thus, there is ample evidence for using valganciclovir to prevent Kaposi sarcoma in high-risk individuals. Operationally, however, it is not yet clear who might benefit most from preventive use of antivirals (see above).
Human [40, 58] . Furthermore, the largest trial of cidofovir to date, which included seven patients with Kaposi sarcoma, found no apparent effect on tumor progression or on HHV-8 viremia [51] . Even if continuous HHV-8 lytic replication is important for the persistence of Kaposi sarcoma tumors, it is possible that once Kaposi sarcoma has developed, these drugs may not suppress HHV-8 replication effectively enough to have clinical benefits. In this case, more potent antiviral regimens could improve outcomes. Alternatively, it may be that despite complete inhibition of viral DNA synthesis, expression of early lytic gene products (e.g. vIL-6 and vGPCR) may still occur at levels sufficient to support Kaposi sarcoma progression [59, 60] . The impact of antivirals on Kaposi sarcoma treatment might be augmented if combined with agents that induce the activation of HHV-8 latently infected cells to undergo lytic replication in vitro, such as valproic acid, hydroxyurea, or glycyrrhizinic acid [61, 62] , but such approaches have not been validated in clinical trials to date. A final potential role for antivirals might be as secondary prophylaxis after a response to ART and/or chemotherapy in order to reduce the risk of relapse [63] , which has not yet been evaluated in clinical trials.
The benefit of various antiviral treatment strategies for other HHV-8-related diseases, particularly MCD, is suggested by some reports [44, [64] [65] [66] [67] [68] , but not others [69] , and definitive data do not exist to recommend specific therapies.
The effects of antiretroviral therapy on human herpesvirus 8-related diseases
In resource-rich areas, the widespread availability of ART has resulted in a dramatic decline in Kaposi sarcoma incidence [70] . Rates of Kaposi sarcoma began slowing with the advent of zidovudine monotherapy, and then fell precipitously with the use of 'highly active' ART combining nucleoside reverse transcriptase inhibitors (NRTIs) with a non-NRTI (NNRTI) or protease inhibitor. The mechanisms by which ART prevents Kaposi sarcoma have not been entirely defined, but it is clear that restoration of immune function plays a central role. HIV itself may also promote the development of Kaposi sarcoma through actions of Tat (reviewed in [71, 72] ).
One recurring and controversial hypothesis is that the individual antiretroviral components of ART regimens, specifically protease inhibitors, may have differential effects on HHV-8 or tumorigenesis that affect Kaposi sarcoma development or response, independently of their effects on HIV replication and immune reconstitution. It should be stressed that a number of observational studies have found similar rates of Kaposi sarcoma incidence and response between HIV-infected patients treated with protease inhibitor-based and NNRTI-based ART [28, [73] [74] [75] 76] . However, these studies were all limited by small numbers of Kaposi sarcoma cases and/ or incomplete detail regarding the type and use of ART regimen. Some of these same data suggest that complete remission of Kaposi sarcoma may occur more often in patients treated with protease inhibitors despite similar control of HIV infection (HIV RNA and CD4 T-cell levels) [28] . In addition, numerous Kaposi sarcoma relapses have been reported after switching from protease inhibitor-based to NNRTI-based ART regimens without virologic or immunologic deterioration [77] [78] [79] . In the absence of convincing clinical evidence for the superiority of protease inhibitors for Kaposi sarcoma, there has been much interest in the fact that individual protease inhibitors variably affect angiogenesis, cell division and invasion, and apoptosis (reviewed in [80, 81] ). Some of these actions by protease inhibitors appear to be mediated through inhibition of the PI3K/Akt signaling, which is upregulated both by latent HHV-8 infection and by vGPCR [82, 83] . The attractiveness of the PI3K/Akt pathway as a target for Kaposi sarcoma treatment is illustrated by the success of the immunosuppressant rapamycin (sirolimus), an inhibitor of mammalian target of rapamycin (a signaling molecule that is downstream of and activated by PI3K/Akt), which is remarkably effective for Kaposi sarcoma in transplant patients [54] and has activity against PEL cell lines [84] . Interestingly, a recent study shows that rapamycin inhibits expression of HHV-8 RTA in vitro, blocking virion production [53 ] . Other mechanisms by which protease inhibitors may interfere with HHV-8 tumorigenesis include inhibition of matrix metalloprotease and proteasome activities. Notably, these properties have sparked an interest in the use of protease inhibitors for other cancer types, leading to clinical trials for a wide variety of solid tumors (reviewed in [80, 85] ).
Another intriguing possibility is that some antiretrovirals directly affect HHV-8 replication. Among several protease inhibitors screened for their ability to inhibit HHV-8 replication using a recombinant virus assay, only nelfinavir showed potent activity at concentrations that are achieved in plasma with standard oral dosing (Table  2) [52 ] . Protease inhibitors act on the HIV aspartyl protease, an enzyme not encoded by HHVs. However, nelfinavir modulates numerous basic cellular processes [80] , one or more of which might disrupt HHV-8 replication. The NRTIs zidovudine and stavudine are phosphorylated by the HHV-8 thymidine kinase (ORF 21) [86, 87] , but appear to have minimal effects on HHV-8 replication in vitro [52 ] .
The varied effects of different protease inhibitors on HHV-8 replication, tumor growth, and angiogenesis indicate the possibility that all ART regimens may not be equally effective for preventing or treating Kaposi sarcoma. This could explain why observational studies that combine all protease inhibitors together, perhaps diluting a benefit of a subset of these agents, may not have discerned an effect of protease inhibitor-based compared to NNRTI-based ART regimens, especially when the number of events is small [28, [73] [74] [75] . Disappointingly, unlike in the United States and Europe, rates of Kaposi sarcoma in sub-Saharan Africa have not declined appreciably even where ART has been provided to a large proportion of those requiring treatment [88] . The vast majority of ART delivered in subSaharan Africa has been nevirapine (NNRTI)-based, raising the possibility that different first-line regimens might offer an advantage in Kaposi sarcoma-endemic populations. Controlled trials are needed to determine which individual ART regimens are optimal for the prevention and treatment of Kaposi sarcoma. Although the use of protease inhibitor-based ART as first-line treatment of Kaposi sarcoma has already been adopted by some clinicians [89] , there are currently no controlled studies to support this practice or guide the choice of individual protease inhibitor. An uncontrolled trial of indinavir in 28 patients with refractory classic (HIVnegative) Kaposi sarcoma observed tumor regression in a minority of individuals [90] , and a phase 3 randomized trial of ART containing a protease inhibitor combination (ritonavir-boosted lopinavir) versus a NNRTI (efavirenz) for mild-moderate AIDS-Kaposi sarcoma is ongoing in Uganda (ClinicalTrials.gov Identifier: NCT00444379). Additional trials are required to determine how best to use available agents -and to guide the development of new therapies -to improve Kaposi sarcoma outcomes.
Conclusion
Despite our increased understanding of HHV-8 pathobiology, the exact mechanisms by which HHV-8 infection causes Kaposi sarcoma, MCD, and PEL remain unclear. Kaposi sarcoma and MCD in particular differ from classical cancers in ways that in part reflect the requirement for ongoing lytic replication. This paradigm squarely frames HHV-8 replication as a therapeutic target for the prevention or treatment of these diseases. Importantly, several drugs that inhibit HHV-8 replication, including (val)ganciclovir and nelfinavir, are already in wide clinical use for other indications and can, therefore, be easily evaluated and repositioned for the specific management of Kaposi sarcoma.
Other protease inhibitors may have specific benefits for Kaposi sarcoma by interfering with cellular processes that are driven by HHV-8 infection. However, the role of HHV-8 DNA synthesis inhibitors and the optimal ART regimen for prevention and treatment of Kaposi sarcoma has yet to be defined. Given the enormous burden of Kaposi sarcoma in sub-Saharan Africa and the poor outcomes of current standard therapies, controlled clinical trials are urgently needed to evaluate these approaches. 
